Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: Final results of a dose-escalation study

被引：0
|
作者：
Frost, A.
Buechert, M.
Unger, C.
Christensen, O.
Wagner, A.
Heinig, R. A.
Scheulen, M. E.
Strumberg, D.
Fasol, U.
Mross, K.
机构：
[1] Tumor Biol Ctr, Freiburg, Germany
[2] Univ Hosp Freiburg, Freiburg, Germany
[3] Bayer HealthCare Pharmaceut, West Haven, CT USA
[4] Bayer Schering Pharma AG, Berlin, Germany
[5] Bayer HealthCare, Wuppertal, Germany
[6] Univ Essen Gesamthsch, Sch Med, Essen, Germany
[7] Univ Hosp Bochum, Marienhosp Herne, Herne, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2558
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
    Francisco Robert
    Alan Sandler
    Joan H. Schiller
    Glenn Liu
    Karen Harper
    Lev Verkh
    Xin Huang
    Jennifer Ilagan
    Lesley Tye
    Richard Chao
    Anne M. Traynor
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 669 - 680
  • [22] A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors
    Gordon, Michael S.
    Springett, Gregory M.
    Su, Yungpo Bernard
    Ould-Kaci, Mahmoud
    Wind, Sven
    Zhao, Yihua
    LoRusso, Patricia M.
    FUTURE ONCOLOGY, 2015, 11 (10) : 1479 - 1491
  • [23] A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
    Harding, James J.
    Telli, Melinda
    Munster, Pamela
    Voss, Martin H.
    Infante, Jeffrey R.
    DeMichele, Angela
    Dunphy, Mark
    Le, Mai H.
    Molineaux, Chris
    Orford, Keith
    Parlati, Frank
    Whiting, Sam H.
    Bennett, Mark K.
    Tannir, Nizar M.
    Meric-Bernstam, Funda
    CLINICAL CANCER RESEARCH, 2021, 27 (18) : 4994 - 5003
  • [24] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Sukhmani K. Padda
    Yelena Krupitskaya
    Laveena Chhatwani
    George A. Fisher
    Alexander D. Colevas
    Melanie San Pedro-Salcedo
    Rodney Decker
    Jane E. Latz
    Heather A. Wakelee
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1013 - 1020
  • [25] Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors
    Wu, Yi-Long
    Cheng, Ying
    Chen, Huajun
    Tu, Haiyan
    Xu, Chongrui
    Wang, Zhen
    Liu, Ying
    Xin, Ying
    Lou, Haizhou
    Wang, Wei
    Chin, Kevin
    Li, Dandan
    Zhao, Di
    Gao, Yanfei
    Xu, Wenping
    Pan, Hongming
    FUTURE ONCOLOGY, 2022, 18 (17) : 2053 - 2062
  • [26] A PHASE I DOSE-ESCALATION STUDY OF EMD 1214063, AN ORAL SELECTIVE CMET INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS
    Naing, A.
    Falchook, G. S.
    Fu, S.
    Amin, H. M.
    Piha-Paul, S. A.
    Hong, D. S.
    Tsimberidou, A. M.
    Wheler, J. J.
    Janku, F.
    Klevesath, M. B.
    Jego, V.
    Johne, A.
    Kurzrock, R.
    ANNALS OF ONCOLOGY, 2012, 23 : 21 - 21
  • [27] A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors
    Molife, L. Rhoda
    Dean, Emma Jane
    Blanco-Codesido, Montserrat
    Krebs, Matthew G.
    Brunetto, Andre T.
    Greystoke, Alastair Peter
    Daniele, Gennaro
    Lee, Lucy
    Kuznetsov, Galina
    Myint, Khin Than
    Wood, Karen
    de las Heras, Begona
    Ranson, Malcolm Richard
    CLINICAL CANCER RESEARCH, 2014, 20 (24) : 6284 - 6294
  • [28] Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma
    Hong, David S.
    Kurzrock, Razelle
    Wheler, Jennifer J.
    Naing, Aung
    Falchook, Gerald S.
    Fu, Siqing
    Kim, Kevin B.
    Davies, Michael A.
    Nguyen, Ly M.
    George, Goldy C.
    Xu, Lucy
    Shumaker, Robert
    Ren, Min
    Mink, Jennifer
    Bedell, Cynthia
    Andresen, Corina
    Sachdev, Pallavi
    O'Brien, James P.
    Nemunaitis, John
    CLINICAL CANCER RESEARCH, 2015, 21 (21) : 4801 - 4810
  • [29] Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
    Wilhelm, Scott M.
    Dumas, Jacques
    Adnane, Lila
    Lynch, Mark
    Carter, Christopher A.
    Schuetz, Gunnar
    Thierauch, Karl-Heinz
    Zopf, Dieter
    INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (01) : 245 - 255
  • [30] Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors
    Infante, Jeffrey R.
    Dees, E. Claire
    Olszanski, Anthony J.
    Dhuria, Shyeilla V.
    Sen, Suman
    Cameron, Scott
    Cohen, Roger B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (28) : 3103 - +
12345